![]() | Sabbe, M., Schleich, F., & Louis, R. (2025). Biologics alter the relationship between FeNO and sputum eosinophils in severe T2 high asthmatics. ERJ Open Research, 00783-2024. doi:10.1183/23120541.00783-2024 Peer Reviewed verified by ORBi |
![]() | Louis, F., Sabbe, M., Schleich, F., Philippe, G., & Louis, R. (December 2024). L’étude clinique du mois. L’étude PROMISE : une confirmation de l’efficacité du benralizumab en vie réelle chez les patients asthmatiques sévères éosinophiliques. Revue Médicale de Liège, 79 (12), 807 - 811. Editorial Reviewed verified by ORBi |
![]() ![]() | Zahraei, H. N., Schleich, F., Louis, G., Gerday, S., SABBE, M., Bougard, N., GUISSARD, F., PAULUS, V., Henket, M., Pétré, B., Donneau, A.-F., & Louis, R. (2024). Evidence for two clusters among non-eosinophilic asthmatics. Annals of Allergy, Asthma and Immunology. doi:10.1016/j.anai.2024.03.012 Peer Reviewed verified by ORBi |
![]() | Schleich, F., SABBE, M., Moermans, C., & Louis, R. (January 2024). Le médicament du mois. Tézépélumab (Tezspire®) : nouveau traitement biologique de l’asthme sévère. Revue Médicale de Liège, 79 (1), 60 - 64. Editorial Reviewed verified by ORBi |